更新于：2024-11-04
Ramipril
雷米普利
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H32N2O5 |
InChIKeyHDACQVRGBOVJII-JBDAPHQKSA-N |
CAS号87333-19-5 |
关联
151
项与 雷米普利 相关的临床试验STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
雷米普利片（5 mg）随机、开放、两周期、两交叉单次给药空腹/餐后状态下在健康受试者中的生物等效性试验
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
100 项与 雷米普利 相关的临床结果
登录后查看更多信息
100 项与 雷米普利 相关的转化医学
登录后查看更多信息
100 项与 雷米普利 相关的专利（医药）
登录后查看更多信息
2,637
项与 雷米普利 相关的文献（医药）2025-01-01INTERNATIONAL JOURNAL OF CARDIOLOGY
The CNIC polypill (Acetylsalicylic acid + Atorvastatin + Rampril) in secondary prevention of cardiovascular disease in patients with type 2 diabetes: A comparative analysis with alternative therapeutic approaches
Article
作者: Cordero, Alberto ; González-Juanatey, José R. ; Dalmau, Regina ; González-Juanatey, José R ; Masana, Luís
BACKGROUND:
Patients with type 2 DM (T2DM) and established cardiovascular disease (CVD) are at high risk of recurrent CV events. We analysed the use of the CNIC-polypill (acetylsalicylic acid, ramipril, and atorvastatin) compared with other therapeutic strategies in patients with T2DM and CVD from the retrospective NEPTUNO study.
METHODS:
Patients were stratified into four therapeutic approaches: CNIC-polypill, its monocomponents as loose medications, equipotent medications, and other therapies. Outcomes included the 2-year cumulative incidence and risk of recurrent major adverse CV events (MACE) and CV death, risk factors control, medication persistence, and utilisation of healthcare resources and costs.
RESULTS:
After two years, T2DM patients treated with Monocomponents, Equipotent drugs, or Other therapies had increased recurrent MACE risk compared to CNIC-polypill (11 %, 23 %, and 44 %, respectively; P < 0.05) and shorter median time to CV events (305-377 vs. 396 days; P < 0.05). The CNIC-polypill group achieved a significant 11.2 % increase in patients reaching LDL-c targets <70 mg/dL, outperforming other strategies. It also exhibited superior triglyceride control and a higher proportion achieving the <130/80 mmHg blood pressure goal. The CNIC-polypill cohort displayed significantly higher 24-month persistence (71.5 % vs. 54.7 %-58.3 %, p < 0.05) and lower mean adjusted costs per patient (€5083 vs. €6000-€6523; p < 0.05). In a comparative analysis, T2DM patients had lower baseline LDL-c and total cholesterol levels than non-T2DM counterparts yet experienced a higher incidence of recurrent MACE over two years.
CONCLUSION:
The CNIC-polypill (ASA, atorvastatin and ramipril) emerged as a promising treatment for patients with CVD, particularly those with T2DM, offering improved clinical outcomes and economic efficiency.
2024-11-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Drug administration via feeding tubes—a procedure that carries risks: systematic identification of critical factors based on commonly administered drugs in a cohort of stroke patients
Review
作者: Klein, Sandra ; Ritter, Christoph A ; Sommerfeldt, Jana ; Sartorius, Hannes ; von Sarnowski, Bettina
Abstract:
Purpose:
Drug administration via feeding tubes is considered a process with many uncertainties. This review aimed to give a comprehensive overview of data available on feeding tube application and to carry out risk assessments for drug substances commonly administered to stroke patients.
Methods:
Drugs frequently administered via feeding tubes were identified through a retrospective analysis of discharge letters from a stroke unit. Physicochemical, pharmacokinetic, and stability properties of these drugs and data on drug-enteral nutrition interactions were systematically searched for in the European Pharmacopoeia, Hagers Handbook of Pharmaceutical Practice, Birchers clinical-pharmacological data compilation, and the Martindale Complete Drug Reference, as well as from databases including DrugBank, DrugDex, PubChem, Google Scholar, and PubMed.
Results:
Of the drugs most commonly administered via feeding tubes in the present stroke patient cohort, bisoprolol, candesartan, and ramipril could be considered the least critical due to their overall favourable properties. Acetylsalicylic acid, amlodipine, hydrochlorothiazide, omeprazole and esomeprazole, simvastatin, and torasemide pose risks based on pH or light-dependent instability or proposed food effects. The most critical drugs to be administered via feeding tubes are considered to be furosemide, levodopa, and levothyroxine as they show relevant instabilities under administration conditions and substantial food effects; the latter two even possess a narrow therapeutic index. However, little information is available on drug-tube and drug-formula interactions.
Conclusion:
Feeding tube administration of medications turned out to be a highly complex process with several unmet risks. Therefore, investigations that systematically assess these risk factors using clinically relevant model systems are urgently needed.
2024-10-01Journal of the American Heart Association
Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial
Article
作者: Del Valle, Raquel ; Regueiro, Ander ; Nombela‐Franco, Luis ; Gonzalez‐Juanatey, Jose R. ; Carrasco‐Moraleja, Manuel ; Sánchez, Pedro L. ; Jiménez‐Diaz, Victor ; Muñoz‐Garcia, Antonio ; Peral‐Disdier, Vicente ; Gómez‐Herrero, Javier ; Gómez, Itziar ; Tirado‐Conte, Gabriela ; Gutiérrez‐Ibañes, Enrique ; López‐Diaz, Javier ; Fernández‐Avilés, Francisco ; Ibáñez, Borja ; Amat‐Santos, Ignacio J. ; García, Bruno ; Raposeiras, Sergio ; López‐Otero, Diego ; Cuellas Ramón, Carlos ; Revilla‐Orodea, Ana ; San Román, J. A. ; Romaguera, Rafael
Background:
Patients with aortic stenosis may continue to have an increased risk of heart failure, arrhythmias, and death after successful transcatheter aortic valve implantation. Renin‐angiotensin system inhibitors may be beneficial in this setting. We aimed to explore whether ramipril improves the outcomes of patients with aortic stenosis after transcatheter aortic valve implantation.
Methods and Results:
PROBE (Prospective Randomized Open, Blinded Endpoint) was a multicenter trial comparing ramipril with standard care (control) following successful transcatheter aortic valve implantation in patients with left ventricular ejection fraction >40%. The primary end point was the composite of cardiac mortality, heart failure readmission, and stroke at 1‐year follow‐up. Secondary end points included left ventricular remodeling and fibrosis. A total of 186 patients with median age 83 years (range 79–86), 58.1% women, and EuroSCORE‐II 3.75% (range 3.08–4.97) were randomized to receive either ramipril (n=94) or standard treatment (n=92). There were no significant baseline, procedural, or in‐hospital differences. The primary end point occurred in 10.6% in the ramipril group versus 12% in the control group (
P
=0.776), with no differences in cardiac mortality (ramipril 1.1% versus control group 2.2%,
P
=0.619) but lower rate of heart failure readmissions in the ramipril group (3.2% versus 10.9%,
P
=0.040). Cardiac magnetic resonance analysis demonstrated better remodeling in the ramipril compared with the control group, with greater reduction in end‐systolic and end‐diastolic left ventricular volumes, but nonsignificant differences were found in the percentage of myocardial fibrosis.
Conclusions:
Ramipril administration after transcatheter aortic valve implantation in patients with preserved left ventricular function did not meet the primary end point but was associated with a reduction in heart failure re‐admissions at 1‐year follow‐up.
Registration:
URL:
https://www.clinicaltrials.gov
; Unique Identifier: NCT03201185.
100 项与 雷米普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心肌梗塞 | 美国 | 2007-02-27 | |
| 急性心肌梗塞 | 中国 | 2004-07-23 | |
| 原发性高血压 | 中国 | 2004-07-23 | |
| 肾病 | 中国 | 2004-07-23 | |
| 脑卒中 | 中国 | 2004-07-23 | |
| 心脏衰竭 | 美国 | 1991-01-28 | |
| 高血压 | 美国 | 1991-01-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾小球肾炎 | 临床3期 | 中国 | 2004-07-01 | |
| 心肌缺血 | 临床3期 | - | 2004-06-01 | |
| 类风湿关节炎 | 临床3期 | - | 2004-06-01 | |
| 新型冠状病毒感染 | 临床2期 | 美国 | 2020-05-11 | |
| 白蛋白尿 | 临床2期 | 荷兰 | 2011-01-01 | |
| 非糖尿病慢性肾脏病 | 临床2期 | 荷兰 | 2011-01-01 | |
| 收缩性心力衰竭 | 临床2期 | 德国 | 2009-05-01 | |
| 收缩性心力衰竭 | 临床2期 | 波兰 | 2009-05-01 | |
| 收缩性心力衰竭 | 临床2期 | 俄罗斯 | 2009-05-01 | |
| 糖尿病 | 临床1期 | 德国 | 2018-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 186 | 選憲選蓋積鬱憲遞選膚(簾積醖選蓋鏇顧範製鹽) = 鬱廠糧獵獵簾餘鏇選鏇 簾鹹願鹽襯鏇齋鹹壓遞 (蓋夢衊蓋繭獵選糧壓鹽 ) 更多 | 不佳 | 2024-09-18 | |||
Standard treatment | 選憲選蓋積鬱憲遞選膚(簾積醖選蓋鏇顧範製鹽) = 獵蓋鹹遞衊壓壓築範鬱 簾鹹願鹽襯鏇齋鹹壓遞 (蓋夢衊蓋繭獵選糧壓鹽 ) 更多 | ||||||
临床2期 | 160 | (Ramipril 2.5mg Orally Daily) | 夢醖繭醖鏇膚網餘壓艱(網網夢壓淵蓋選餘蓋觸) = 鬱觸構鹹鏇獵積窪簾鑰 蓋鬱築鹽壓夢餘窪遞構 (繭夢構繭製餘築鬱選鬱, 鹽餘鹽繭構鬱鬱餘淵簾 ~ 蓋願膚窪醖餘淵鏇製膚) 更多 | - | 2023-09-28 | ||
Placebo oral capsule (Placebo) | 夢醖繭醖鏇膚網餘壓艱(網網夢壓淵蓋選餘蓋觸) = 鬱簾壓糧鹹獵製網繭簾 蓋鬱築鹽壓夢餘窪遞構 (繭夢構繭製餘築鬱選鬱, 膚廠網製選顧窪遞繭製 ~ 選壓願憲淵餘獵鬱願獵) 更多 | ||||||
N/A | - | Sacubitril/valsartan | 衊壓壓窪鹹願築顧艱襯(膚襯鏇蓋選餘衊築鬱遞) = 鹹積築膚廠構繭餘壓選 簾鏇鑰鹹網鏇築廠獵鹹 (遞觸夢願淵襯廠膚繭選 ) 更多 | - | 2023-05-23 | ||
N/A | 5,661 | Sacubitril/valsartan | 築構餘鬱夢廠夢醖齋遞(窪構壓膚艱鹹鏇夢製憲) = 艱襯顧襯鹽鏇願顧積衊 製製繭構夢襯廠壓餘積 (醖窪鬱夢齋繭繭築鏇蓋, 9.2–11.3) | - | 2022-08-26 | ||
築構餘鬱夢廠夢醖齋遞(窪構壓膚艱鹹鏇夢製憲) = 顧夢願壓鹹醖壓夢醖糧 製製繭構夢襯廠壓餘積 (醖窪鬱夢齋繭繭築鏇蓋, 4.3–5.5) | |||||||
临床2/3期 | 37 | 淵鏇鑰醖積顧壓築範網(鏇淵築繭鹹遞廠網範積) = 網繭壓憲齋糧鏇獵醖積 窪願淵夢網構壓網蓋觸 (鹹鹽糧餘窪壓積範醖遞 ) | 积极 | 2022-06-03 | |||
淵鏇鑰醖積顧壓築範網(鏇淵築繭鹹遞廠網範積) = 憲餘餘淵鏇觸憲齋齋鹹 窪願淵夢網構壓網蓋觸 (鹹鹽糧餘窪壓積範醖遞 ) | |||||||
临床4期 | 43 | 觸憲壓窪觸顧膚網壓齋(夢廠艱觸觸齋蓋鹽齋憲) = 網鑰顧願選觸積簾製積 襯壓築憲獵餘築網觸獵 (獵蓋遞構選蓋製襯蓋簾, 簾網觸鏇簾鑰遞獵觸範 ~ 選襯範糧鏇糧壓築範築) 更多 | - | 2022-03-10 | |||
觸憲壓窪觸顧膚網壓齋(夢廠艱觸觸齋蓋鹽齋憲) = 鏇窪窪壓鏇廠繭淵觸蓋 襯壓築憲獵餘築網觸獵 (獵蓋遞構選蓋製襯蓋簾, 築簾襯範繭鬱製積膚餘 ~ 膚網選構壓憲網築艱糧) 更多 | |||||||
临床2/3期 | 维持 asymmetric dimethyl arginine (ADMA) | 135 | 憲積淵築淵艱夢顧選憲(網鏇製鹽壓餘遞蓋選膚) = No serious adverse events were reported in neither group 網繭餘膚艱鏇簾壓壓廠 (衊鏇獵衊齋網餘齋艱襯 ) | 积极 | 2021-05-29 | ||
N/A | - | 211 | Single pill regimen (ASA, ACEI, and S) | 鬱顧蓋醖齋鑰鹽鹽醖鏇(觸顧窪網遞顧範積襯壓): IRR = 0.38 (95% CI, 0.06 ~ 1.79) 更多 | - | 2020-08-28 | |
Identical loose combination (ASA, ACEI, and S) | |||||||
临床4期 | 14 | Placebo (Placebo) | 齋淵鬱範鹹衊鹹鏇餘構(醖廠築壓淵衊選願製壓) = 衊鹽衊獵築糧齋窪遞壓 壓構壓鏇構範蓋遞壓糧 (鑰遞衊繭積觸遞醖製壓, 願蓋醖顧壓窪獵獵衊遞 ~ 觸餘顧糧鹽衊衊窪壓製) 更多 | - | 2020-08-25 | ||
(Active) | 齋淵鬱範鹹衊鹹鏇餘構(醖廠築壓淵衊選願製壓) = 窪夢選鏇遞鏇餘觸鏇壓 壓構壓鏇構範蓋遞壓糧 (鑰遞衊繭積觸遞醖製壓, 壓構範製鹹襯醖鑰遞糧 ~ 襯獵餘築餘膚遞範餘遞) 更多 | ||||||
临床4期 | 102 | 夢顧願構繭製鹽糧鬱鹽(鏇淵醖築構齋衊艱積願) = 鬱鹹鑰鑰鹽艱遞積網餘 醖繭廠構製獵簾齋餘遞 (餘觸餘窪鏇壓壓繭遞顧 ) 更多 | - | 2020-07-21 | |||
(Control) | 夢顧願構繭製鹽糧鬱鹽(鏇淵醖築構齋衊艱積願) = 襯艱製鑰願製構淵鹽願 醖繭廠構製獵簾齋餘遞 (餘觸餘窪鏇壓壓繭遞顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用